Obinutuzumab Pregnancy and Breastfeeding Warnings
Obinutuzumab is also known as: Gazyva
Obinutuzumab Pregnancy Warnings
This drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. AU TGA pregnancy category: C US FDA pregnancy category: C Comments: -Women of childbearing potential should use effective contraception during and for 12 months after treatment. (AU, US) -Women of childbearing potential should use effective contraception during and for 18 months after treatment. (UK) -Infants born to mothers who have been exposed to this drug during pregnancy should not receive live vaccines until their B-cell levels are within normal ranges.
Animal studies (in cynomolgus monkeys) have failed to reveal evidence of teratogenicity at exposures that were 2.4 times the recommended human exposure. However, B cells were completely depleted in offspring at day 28 postpartum. B-Cell counts and immunologic function returned to normal within 6 months after birth. There are no controlled data in human pregnancy. AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details. FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Obinutuzumab Breastfeeding Warnings
A decision should be made whether to discontinue nursing, or discontinue the drug, taking into account the importance of the drug to the mother. Excreted into human milk: Unknown Excreted into animal milk: Yes Comments: -The effects in the nursing infant are unknown. -Human IgG is excreted in human milk and this drug is a monoclonal antibody of the IgG1 subclass. -Women should be advised to discontinue breast-feeding during therapy and for 12 months after the last dose. (AU) -Women should be advised to discontinue breast-feeding during therapy and for 18 months after the last dose. (UK)
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.